- Home
- OPTN vs ALEC Comparison
OPTN vs ALEC Comparison
Compare OPTN & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPTN
- ALEC
- Stock Information
- Founded
- OPTN 2010
- ALEC 2013
- Country
- OPTN United States
- ALEC United States
- Employees
- OPTN N/A
- ALEC N/A
- Industry
- OPTN Biotechnology: Pharmaceutical Preparations
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OPTN Health Care
- ALEC Health Care
- Exchange
- OPTN Nasdaq
- ALEC Nasdaq
- Market Cap
- OPTN 92.8M
- ALEC 101.1M
- IPO Year
- OPTN 2017
- ALEC 2019
- Fundamental
- Price
- OPTN $9.39
- ALEC $1.17
- Analyst Decision
- OPTN Hold
- ALEC Buy
- Analyst Count
- OPTN 3
- ALEC 7
- Target Price
- OPTN $9.00
- ALEC $4.70
- AVG Volume (30 Days)
- OPTN 32.1K
- ALEC 928.9K
- Earning Date
- OPTN 05-20-2025
- ALEC 05-08-2025
- Dividend Yield
- OPTN N/A
- ALEC N/A
- EPS Growth
- OPTN N/A
- ALEC N/A
- EPS
- OPTN N/A
- ALEC N/A
- Revenue
- OPTN $78,226,000.00
- ALEC $88,339,000.00
- Revenue This Year
- OPTN $30.49
- ALEC N/A
- Revenue Next Year
- OPTN $13.51
- ALEC $376.51
- P/E Ratio
- OPTN N/A
- ALEC N/A
- Revenue Growth
- OPTN 10.20
- ALEC N/A
- 52 Week Low
- OPTN $4.82
- ALEC $0.87
- 52 Week High
- OPTN $20.03
- ALEC $6.78
- Technical
- Relative Strength Index (RSI)
- OPTN 76.14
- ALEC 51.49
- Support Level
- OPTN $9.37
- ALEC $0.97
- Resistance Level
- OPTN $9.45
- ALEC $1.34
- Average True Range (ATR)
- OPTN 0.08
- ALEC 0.11
- MACD
- OPTN -0.07
- ALEC 0.01
- Stochastic Oscillator
- OPTN 80.71
- ALEC 53.68
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.